| Study | Reason for exclusion |
|---|---|
| Bieron 2005 | Not double‐blind |
| Ciuffetti 1991 | Reported biochemical properties, not TWD or PFWD |
| Dawson 1999 | Single‐blind study |
| Dettori 1989 | Single‐blind for acenocoumarol; therefore, no true double‐blinding of all trial agents. Outcomes measured in time, not distance |
| Ehrly 1986 | Different outcome measures such as muscle tissue oxygen pressure |
| Ehrly 1987 | Different outcome measures such as muscle tissue oxygen pressure |
| Farkas 1993 | Duration of therapy only 2 weeks |
| Fossat 1995 | Different outcome measures such as leukocyte activation |
| Geppert 2017 | Short term study – < 4 weeks' treatment |
| Guest 2005 | Cost comparison with no clinical outcomes |
| Hepp 1996 | Not double‐blind |
| Horowitz 1982 | Variable doses of pentoxifylline |
| Incandela 2002 | Reported microcirculatory parameters |
| Kellner 1976 | Participants with Fontaine stage II and III; results for the 2 groups not presented separately |
| Luk'Janov 1995 | Different outcome measures such as haemorheological and haemodynamic measures evaluated; minimal data on walking distance |
| Milio 2003 | Not double‐blind |
| Milio 2006 | Single‐blind study |
| Panchenko 1997 | Open study – no blinding |
| Pignoli 1985 | Not double‐blind |
| Poggesi 1985 | Different outcomes such as circulatory changes and prostaglandin synthesis |
| Regenthal 1991 | Not double‐blind |
| Reilly 1987 | All included participants single‐blind after first 8 weeks; therefore, no true randomisation |
| Rodin 1998a | Not a double‐blind clinical trial |
| Rodin 1998b | Not a double‐blind clinical trial |
| Roekaerts 1984 | Participants with Fontaine stage II and III; results not presented separately for the 2 groups |
| Rudofsky 1987 | Only 1–2 weeks of treatment provided |
| Rudofsky 1988 | Only 2 weeks of treatment provided |
| Rudofsky 1989 | Only 2 weeks of treatment provided |
| Scheffler 1991 | Not a double‐blind study. Training for participants provided |
| Scheffler 1994 | Not a double‐blind study. Comparison with exercise performed |
| Schubotz 1976 | Participants with symptoms of critical limb ischaemia |
| Shustov 1997 | Open controlled trial |
| Singh 2009 | Open study |
| Skovborg 1983 | Unable to determine if randomised and double‐blind over extended time period |
| Strano 1984 | Participants with stage Fontaine stage II and III; results not presented separately for the 2 groups |
| Strano 2002 | Open study |
| Thomson 1990 | Participants with symptoms of critical limb ischaemia |
| Tonak 1977 | Participants with Fontaine stage II and III; results not presented separately for the 2 groups |
| Triebe 1992 | Open study |
| Tsang 1994 | Different outcome measures such as albumin/creatinine ratio, etc. |
| Wang 2003 | Different outcome measures such as lipoprotein cholesterol concentrations |
PFWD: pain‐free walking distance; TWD: total walking distance.